Header Logo

Connection

JAMES WELSH to Aged

Back to Details
This is a "connection" page, showing publications JAMES WELSH has written about Aged.
JAMES WELSH
Connection Strength
0.961
Aged
  1. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
    View in: PubMed
    Score: 0.036
  2. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.030
  3. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.030
  4. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):196-203.
    View in: PubMed
    Score: 0.028
  5. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer. 2020 Jan; 8(1).
    View in: PubMed
    Score: 0.028
  6. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
    View in: PubMed
    Score: 0.028
  7. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.028
  8. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
    View in: PubMed
    Score: 0.028
  9. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
    View in: PubMed
    Score: 0.028
  10. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019 Feb/Mar; 42(2):55-64.
    View in: PubMed
    Score: 0.027
  11. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1141-1148.
    View in: PubMed
    Score: 0.025
  12. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.023
  13. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
    View in: PubMed
    Score: 0.019
  14. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol. 2014 Oct; 190(11):979-86.
    View in: PubMed
    Score: 0.019
  15. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.018
  16. Cardiac ?8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8.
    View in: PubMed
    Score: 0.018
  17. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol. 2013 Mar; 106(3):327-32.
    View in: PubMed
    Score: 0.018
  18. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.017
  19. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.017
  20. Correlation of three different approaches of small bowel delineation and acute lower gastrointestinal toxicity in adjuvant pelvic intensity-modulated radiation therapy for endometrial cancer. Technol Cancer Res Treat. 2012 Aug; 11(4):353-9.
    View in: PubMed
    Score: 0.017
  21. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
    View in: PubMed
    Score: 0.016
  22. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e391-8.
    View in: PubMed
    Score: 0.016
  23. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40.
    View in: PubMed
    Score: 0.016
  24. A planning study for palliative spine treatment using StatRT and megavoltage CT simulation. J Appl Clin Med Phys. 2010 Oct 30; 12(1):3348.
    View in: PubMed
    Score: 0.015
  25. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6.
    View in: PubMed
    Score: 0.015
  26. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1251-5.
    View in: PubMed
    Score: 0.014
  27. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):159-65.
    View in: PubMed
    Score: 0.012
  28. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 09; 12(10).
    View in: PubMed
    Score: 0.010
  29. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
    View in: PubMed
    Score: 0.009
  30. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2022 Feb; 40(2):115-123.
    View in: PubMed
    Score: 0.008
  31. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2022 Jan; 40(1):26-34.
    View in: PubMed
    Score: 0.008
  32. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Front Immunol. 2021; 12:719285.
    View in: PubMed
    Score: 0.008
  33. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457.
    View in: PubMed
    Score: 0.008
  34. Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. Gynecol Oncol. 2021 06; 161(3):645-652.
    View in: PubMed
    Score: 0.008
  35. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
    View in: PubMed
    Score: 0.007
  36. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol. 2021 01; 154:187-193.
    View in: PubMed
    Score: 0.007
  37. Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617. Clin Cancer Res. 2020 09 01; 26(17):4643-4650.
    View in: PubMed
    Score: 0.007
  38. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open. 2020 04 01; 3(4):e203277.
    View in: PubMed
    Score: 0.007
  39. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 06 01; 107(2):261-269.
    View in: PubMed
    Score: 0.007
  40. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):90-99.
    View in: PubMed
    Score: 0.007
  41. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 06 01; 5(6):872-878.
    View in: PubMed
    Score: 0.007
  42. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.007
  43. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019 07; 136:136-142.
    View in: PubMed
    Score: 0.007
  44. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 07; 20(4):e480-e488.
    View in: PubMed
    Score: 0.007
  45. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018 11; 19(6):e885-e891.
    View in: PubMed
    Score: 0.006
  46. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
    View in: PubMed
    Score: 0.006
  47. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018 08 01; 4(8):e174504.
    View in: PubMed
    Score: 0.006
  48. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
    View in: PubMed
    Score: 0.006
  49. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018 09; 128(3):505-512.
    View in: PubMed
    Score: 0.006
  50. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.006
  51. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer. 2018 07; 19(4):e517-e528.
    View in: PubMed
    Score: 0.006
  52. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018 Mar; 126(3):499-505.
    View in: PubMed
    Score: 0.006
  53. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922.
    View in: PubMed
    Score: 0.006
  54. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
    View in: PubMed
    Score: 0.006
  55. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.006
  56. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017 11; 12(11):1696-1703.
    View in: PubMed
    Score: 0.006
  57. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):433-441.
    View in: PubMed
    Score: 0.006
  58. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
    View in: PubMed
    Score: 0.006
  59. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):770-777.
    View in: PubMed
    Score: 0.006
  60. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 03; 18(2):141-148.
    View in: PubMed
    Score: 0.006
  61. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.006
  62. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203.
    View in: PubMed
    Score: 0.006
  63. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):63-71.
    View in: PubMed
    Score: 0.006
  64. Single Nucleotide Polymorphisms in CBLB, a?Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 07; 17(4):253-262.e5.
    View in: PubMed
    Score: 0.005
  65. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015 Jul; 6(4):324-31.
    View in: PubMed
    Score: 0.005
  66. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.005
  67. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014 Dec; 149(12):1244-53.
    View in: PubMed
    Score: 0.005
  68. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
    View in: PubMed
    Score: 0.005
  69. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56.
    View in: PubMed
    Score: 0.005
  70. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.005
  71. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60.
    View in: PubMed
    Score: 0.005
  72. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014 Aug; 112(2):256-61.
    View in: PubMed
    Score: 0.005
  73. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
    View in: PubMed
    Score: 0.005
  74. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.005
  75. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10.
    View in: PubMed
    Score: 0.005
  76. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
    View in: PubMed
    Score: 0.004
  77. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
    View in: PubMed
    Score: 0.004
  78. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013 May; 24(5):1312-9.
    View in: PubMed
    Score: 0.004
  79. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1060-70.
    View in: PubMed
    Score: 0.004
  80. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.004
  81. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
    View in: PubMed
    Score: 0.004
  82. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.004
  83. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.004
  84. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci. 2012 May; 103(5):945-50.
    View in: PubMed
    Score: 0.004
  85. Postmastectomy radiotherapy with integrated scar boost using helical tomotherapy. Med Dosim. 2012; 37(3):233-9.
    View in: PubMed
    Score: 0.004
  86. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.004
  87. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33.
    View in: PubMed
    Score: 0.004
  88. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 01; 79(3):835-41.
    View in: PubMed
    Score: 0.004
  89. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24.
    View in: PubMed
    Score: 0.003
  90. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology. 2008; 75(3-4):186-91.
    View in: PubMed
    Score: 0.003
  91. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev. 2008 Dec; 34(8):719-27.
    View in: PubMed
    Score: 0.003
  92. Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat. 2009 Mar; 114(2):307-13.
    View in: PubMed
    Score: 0.003
  93. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):166-71.
    View in: PubMed
    Score: 0.002
  94. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):455-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.